
Summary of Grifols’ New Clinical Trials
The pharmaceutical company Grifols—has started dosing patients in the final stage (Phase 3) of two clinical trials. The company is trying to get approval to

The pharmaceutical company Grifols—has started dosing patients in the final stage (Phase 3) of two clinical trials. The company is trying to get approval to

Editor’s Note: This article was shared with us by our friends at the AAMDS International Foundation. To see the article in its original format, please

A newly reported case from Nanchang University suggests that efgartigimod, a neonatal Fc receptor (FcRn) blocker approved for generalized myasthenia gravis, may offer a promising

Merck has reported positive topline findings from the Phase 3 KEYNOTE-C93 trial, demonstrating that pembrolizumab (KEYTRUDA®) significantly extended progression-free survival (PFS) compared with standard platinum-based

If you or a loved one has ever survived a stroke, you know that the hardest part of the journey often begins after you leave

Editor’s Note: This article was originally written and submitted to us by Regina Portnoy. When people think about leadership in clinical research, they often think

Editor’s Note: This is part 2 of a 3-part caregiver story, submitted to us by Joan Foster, who was a caregiver for her husband Charles’

As reported on Inside Precision Medicine, for years, a chronic spinal cord injury (SCI) has felt like a permanent biological roadblock. When the spinal cord

Thoughts occur in the mind, when the electrical circuits in the brain through neurons and synapses and chemicals all function together. Processes of the mind

As reported on Fierce Pharma, Huyabio has reported encouraging Phase 3 results for its investigational oral HDAC inhibitor, HBI-8000, when used alongside Bristol Myers Squibb’s

I was diagnosed with myasthenia gravis, or MG, in 2021 when I was in my early 20s. My journey began at a friend’s birthday party

Editor’s Note: This is part 2 of a 3-part caregiver story, submitted to us by Joan Foster, who was a caregiver for her husband Charles’

As reported on PharmaBiz, AtaiBeckley has announced a key milestone in the development of its investigational depression therapy, VLS-01, with the final participant now dosed

Editor’s Note: Patient Worthy is honored to share this story, originally written by Anne and Jerry van Wyk, and shared with us by our friends

Every day, parents just like me sit in doctors’ offices searching for answers. They know something isn’t quite right. Maybe their child isn’t meeting milestones.

As reported on Vermont Biz, researchers at the University of Vermont (UVM) and biotechnology company RS Oncology have reported encouraging results from an early-stage clinical

For more than a century Alzheimer’s disease has been thought to be incurable. But a recent study published in the New England Journal of Medicine

Editor’s Note: This is part 1 of a 3-part caregiver story, submitted to us by Joan Foster, who was a caregiver for her husband Charles’
hATTRNextGen Do you know your risk for hereditary amyloidosis ? ... See MoreSee Less
This content isn't available right now
When this happens, it's usually because the owner only shared it with a small group of people, changed who can see it or it's been deleted.
Fabry Support & Information GroupIndividuals and families affected by Fabry disease are invited to join FSIG at WORLDFair 2026 on September 18 at the University of Minnesota Landscape Arboretum in Chaska, Minnesota. This free educational event led by the Genetics Department of University of Minnesota Twin Cities, offers an opportunity to connect with experts, learn about the latest developments in Fabry disease research and care, and meet others who understand the rare disease journey. Whether you attend in person or via Zoom, you'll gain valuable information, encouragement, and community. Reserve your spot today. REGISTER at worldfair.health.
We look forward to seeing you!
#FSIG30 #PatientEducation #FabryDisease #RareDisease #EmpoweringPatients #Research #LysosomalStorageDiseases
... See MoreSee Less

© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
What best describes you when it comes to rare disease? (check all that apply)
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.